Skip to main content
. 2022 Sep 27;52(10):721–736. doi: 10.4070/kcj.2022.0234

Table 1. The summary for TAVR trials.

Company TAVR valve Study Surgical risk Number of patients assigned to TAVR Follow-up duration Mortality (%) Cardiovascular events (%) Major vascular complications (%) Incidence of new pacemaker (%) Moderate/Severe PVR (%)
Edwards SAPIEN THV PARTNER Cohort B49) Inoperable 179 1 year 30.7 10.6 22.3 4.5 10.5
SAPIEN THV PARTNER Cohort A59) High-risk 348 2 years 35.0 11.2 11.6 7.2 6.9
SAPIEN XT PARTNER 252) Intermediate-risk 1,011 2 years 16.7 12.7 8.6 11.8 3.7*
SAPIEN 3 PARTNER 354) Low-risk 496 1 year 1.0 1.2 2.8 7.3 0.6*
Medtronic Core Valve Core Valve Extreme Risk Pivotal60) Inoperable 489 1 year 24.3 7.0 8.4 26.2 4.3
Core Valve Core Valve High Risk50) High-risk 394 1 year 14.2 8.8 6.2 22.3 6.1
Core Valve NOTION61) >70 years 145 1 year 4.9 5.0 5.6* 38.0 15.7
Core Valve SURTAVI62) Intermediate-risk 864 2 years 11.4 10.0 6.0* 25.9* 5.3
Core Valve Evolut R
Core Valve Evolut PRO FORWARD63) High-risk 1,038 30 days 1.9 2.8 6.5 19.7 2.0
Core Valve Evolut PRO Medtronic Evolut PRO US Clinical study53) Extreme or high-risk 60 30 days 1.7 1.7 10.0 11.8 0*
Core Valve Evolut PRO The International FORWARD PRO study64) High or greater risk 629 30 days 4.8 3.8 3.0 20.7 1.8
Core Valve Evolut R Low Risk55) Low-risk 734 2 years 5.3 4.1 3.8 19.4 3.5*
Core Valve Evolut R
Core valve Evolut PRO

TAVR = transcatheter aortic valve replacement.

The incidence is reported based on the follow-up duration of each study, but the following are the exceptions; *Results at 30 days; Results at discharge; Results at one year.

With permission from Bourantas CV, Modolo R, Baumbach A, et al. The evolution of device technology in transcatheter aortic valve implantation. EuroIntervention 2019;14:e1826-33.65)